Development of novel chimeric antigen receptor-expressing T cells promoting immune cell infiltration and survival in the tumor tissue

2016 Fiscal Year Final Research Report

• Project/Area Number: 26830107
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Yamaguchi University
• Principal Investigator: ADACHI Keishi 山口大学, 医学(系)研究科(研究院), 助教 (40598611)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 次世代型キメラ抗原受容体発現T細胞 / サイトカイン / ケモカイン / がん / 抗がん効果

Outline of Final Research Achievements

The goal of this project is to generate a novel cancer therapy using the next generation chimeric antigen receptor (CAR)-expressing T cell that exerts anti-cancer effect more effectively than the conventional one. So far, the following results have been obtained;
1) The next generation CAR-T cell that concomitantly expresses CAR specific to a tumor antigen, a cytokine committing to T cell survival, and a chemokine inducing migration of T cells was generated. 2) The next generation CAR-T cells exerted more potent anti-tumor effects than the conventional one in several murine tumor models. 3) Molecular mechanisms underlying the potent tumoricidal efficacy of the next generation CAR-T cells were elucidated.

Free Research Field

免疫学